ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IPSC Century Therapeutics Inc

3.96
0.29 (7.90%)
Mar 01 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 168,110
Bid Price 3.54
Ask Price 4.05
News -
Day High 4.00

Low
1.28

52 Week Range

High
5.3399

Day Low 3.54
Company Name Stock Ticker Symbol Market Type
Century Therapeutics Inc IPSC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.29 7.90% 3.96 19:57:30
Open Price Low Price High Price Close Price Prev Close
3.66 3.54 4.00 3.96 3.67
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,113 168,110 $ 3.84 $ 646,195 - 1.28 - 5.3399
Last Trade Time Type Quantity Stock Price Currency
17:31:45 5 $ 3.92 USD

Century Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
237.54M 59.83M - 5.2M -130.93M -2.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Century Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IPSC Message Board. Create One! See More Posts on IPSC Message Board See More Message Board Posts

Historical IPSC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.964.003.44853.7299,3610.000.00%
1 Month4.204.883.44854.20373,624-0.24-5.71%
3 Months2.384.882.143.81239,3021.5866.39%
6 Months2.504.881.282.94187,0081.4658.40%
1 Year4.505.33991.283.13149,965-0.54-12.00%
3 Years19.5032.8991.2810.68146,525-15.54-79.69%
5 Years19.5032.8991.2810.68146,525-15.54-79.69%

Century Therapeutics Description

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.

Your Recent History

Delayed Upgrade Clock